SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)

NEW YORK, May 12, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Kymera Therapeutics, Inc. (NASDAQ: KYMR) on behalf of the company's shareholders.  The investigation seeks to determine whether Kymera Therapeutics's directors breached their fiduciary duties in connection with recent corporate actions.

PRNewsWire • May 12, 2026

Kymera Therapeutics, Inc. (KYMR) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Kymera Therapeutics, Inc. (KYMR) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • 21 hours ago

Kymera Therapeutics to Participate in Upcoming May Investor Conferences

WATERTOWN, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events:

GlobeNewsWire • May 6, 2026

Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week

KT-579 demonstrated activity comparable or superior to approved and clinically active therapies in preclinical IBD models

GlobeNewsWire • May 5, 2026

KYMR Q1 Earnings Top Estimates, Revenues Gain on GILD Collaboration

Kymera Therapeutics tops Q1 revenue estimates on strong Gilead collaboration, as pipeline advances and KT-200 milestone deal boost outlook.

Zacks Investment Research • May 1, 2026

Kymera Therapeutics, Inc. (KYMR) Q1 2026 Earnings Call Transcript

Kymera Therapeutics, Inc. (KYMR) Q1 2026 Earnings Call Transcript

Seeking Alpha • Apr 30, 2026

Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update

KT-621 (STAT6) parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively FDA granted Fast Track designation to KT-621 for the treatment of moderate to severe asthma, in addition to prior Fast Track designation for moderate to severe atopic dermatitis KT-579 (IRF5) Phase 1 healthy volunteer trial ongoing, with data expected in 2H26 Gilead Sciences exercised its option to exclusively license KT-200, a first-in-class, oral CDK2 molecular glue degrader, generating a $45 million milestone, with IND planned in 2027 Well-capitalized with $1.55 billion in cash as of March 31, 2026, and runway into 2029 Company to hold video conference call and webcast today at 8:30 a.m. ET WATERTOWN, Mass.

GlobeNewsWire • Apr 30, 2026

Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates

Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.89. This compares to a loss of $0.82 per share a year ago.

Zacks Investment Research • Apr 30, 2026

Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026

WATERTOWN, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report first quarter 2026 financial results on April 30, 2026. The Company will host a video conference call and webcast at 8:30 a.m. ET that day.

GlobeNewsWire • Apr 23, 2026

KYMR Stock Up as FDA Grants Fast Track Designation to Asthma Drug

Kymera Therapeutics shares jump after FDA grants Fast Track to KT-621 for eosinophilic asthma, spotlighting its first-in-class STAT6 degrader potential.

Zacks Investment Research • Apr 14, 2026